Statins decrease the risk of decompensation in hepatitis B virus– and hepatitis C virus–related cirrhosis: A population‐based study
Fu‐Ming Chang, Yen‐Po Wang, Hui‐Chu Lang, Chia‐Fen Tsai, Ming‐Chih Hou, Fa‐Yauh Lee, Ching‐Liang Lu – 20 March 2017 – Statin use decreases the risk of decompensation and mortality in patients with cirrhosis due to hepatitis C virus (HCV). Whether this beneficial effect can be extended to cirrhosis in the general population or cirrhosis due to other causes, such as hepatitis B virus (HBV) infection or alcohol, remains unknown. Statin use also decreases the risk of hepatocellular carcinoma (HCC) in patients with chronic HBV and HCV infection.